Viridian Therapeutics, Inc.
NASDAQ: VRDN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen F. Mahoney
- Employees
- 143
- Headquarters
- Waltham, United States
- IPO year
- 2014
- Market cap
- $1.6B
- Website
- https://www.viridiantherapeutics.com
Loading VRDN…
Loading profile data…Frequently asked questions about VRDN
What does Viridian Therapeutics, Inc. (VRDN) do?
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features V...
Where does VRDN trade?
Viridian Therapeutics, Inc. (VRDN) trades on the NASDAQ Capital Market.
What sector is VRDN in?
Viridian Therapeutics, Inc. (VRDN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Viridian Therapeutics, Inc.?
Stephen F. Mahoney is the chief executive officer of Viridian Therapeutics, Inc. (VRDN).
Where is Viridian Therapeutics, Inc. headquartered?
Viridian Therapeutics, Inc. is headquartered in United States.
Does VRDN pay a dividend?
Viridian Therapeutics, Inc. (VRDN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VRDN go public?
Viridian Therapeutics, Inc. (VRDN) completed its initial public offering in 2014.